Clinical Application of MicroRNAs in Breast Cancer Treatment

Ai Hironaka-Mitsuhashi, Shin Takayama, Kenjiro Jimbo, Akihiko Suto, Akihiko Shimomura, Takahiro Ochiya

Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan
Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan

ARTICLE INFO

Received: 26 July 2021
Revised: 29 September 2021
Accepted: 10 October 2021

ABSTRACT

Background: Recurrence of breast cancer remains a critical problem. Therefore, it is imperative to identify biomarkers that accurately reflect disease state and develop novel drug therapies that are effective even after recurrence. MicroRNAs (miRNAs) are involved in the malignant transformation of various tumors. Circulating miRNAs are promising biomarkers for the diagnosis and treatment of cancers. Additionally, miRNAs are regarded as next-generation drug targets. Currently, various clinical trials are being conducted for anticancer drugs using miRNAs. In this review, we summarized recent studies on miRNA functions and circulating miRNAs in breast cancer, and discussed the status of miRNAs as drug discovery candidates. We also discussed the role of extracellular vesicles (EVs) in the clinical application of miRNAs.

Methods: Relevant articles published from 2002 to 2021 were acquired from PubMed database using the following key words: “miRNA” and “breast neoplasia”. Clinical trial data were retrieved from the database, ClinicalTrials.gov.

Results: Regulating these miRNAs may provide a new therapeutic strategy. Furthermore, miRNAs may be useful diagnostic and prognostic biomarkers for breast cancer. In addition, miRNAs have potential as anticancer agents, and may also be used in combination with other therapies to enhance the efficacies of other drugs.

Conclusion: In summary, miRNAs have shown promise as biomarkers and therapeutic targets. In addition, EVs will be the key to expanding the applications of miRNAs.

INTRODUCTION

According to GLOBOCAN statistics, 2.3 million people worldwide have breast cancer. While good survival rates for breast cancer patients have been obtained with existing drugs, recurrence is often observed 10 years after curative resection, and in most patients, it cannot be cured. In women, breast cancer is the leading cause of cancer-related deaths. Therefore, it is imperative to discover biomarkers that accurately reflect the disease state of patients. There is also an urgent need to discover novel drug therapies that offer therapeutic effects even after recurrence.

MicroRNAs (miRNAs) regulate the expression of several genes and proteins by negatively controlling gene expression. In general, miRNAs bind to complementary sequence sites present in the 3'-untranslated region (UTR) of a target mRNA and induce translational inhibition or degradation; however, miRNAs may act as positive regulators if a...
complementary sequence site is present in the 5′-UTR. Since miRNAs do not require perfect sequence complementarity to bind to the target, one miRNA can suppress the expression of multiple mRNAs. Thus, miRNAs are involved in virtually all the biological processes, including development, differentiation, and metabolism, contributing to the maintenance of homeostasis. Abnormal expression of miRNAs has been observed in many diseases, such as allergies, asthma, diabetes, infectious diseases, and cancers. The abnormal expression of miRNAs in cancer was first reported by Croce et al. in 2002. It has been observed that miRNAs are involved in the malignant transformation of various cancer types, including breast cancer. Currently, information about all previously discovered miRNAs can be found in public databases, and data on more than 2,600 human mature miRNA sequences are present in the miRbase database (http://www.mirbase.org).

It is now known that miRNAs are transported to surrounding cells via extracellular vesicles (EVs). All types of cells can secrete EVs that contain various substances such as nucleic acids, lipids, and proteins. An increase in EV secretion is observed in cancer patients and is termed cancer EVs. Cancer EVs have been suggested as potential biomarkers and therapeutic targets. The functional roles of miRNAs mediated via cancer EVs have been elucidated in several studies, suggesting that regulating miRNAs involved in cell-cell communication will provide a new therapeutic strategy in treating cancers. Since novel targets for low molecular weight compounds, the mainstay of drug discovery, have been decreasing, miRNAs are regarded as next-generation drug targets.

Circulating miRNAs are considered as promising biomarkers for diagnosis and treatment and are easy to incorporate into daily medical care. Most circulating miRNAs are co-fractionated with proteins such as Argonaute 2, which are bound to high-density lipoproteins or encapsulated in 50–150 nm EVs called exosomes, granting stability to the miRNAs in the extracellular environment. As a result, extracellular miRNAs can be detected in other body fluids such as blood, tears, breast milk, and saliva. Currently, several clinical trials for liquid biopsies using circulating miRNAs have been conducted for multiple cancers, including breast cancer.

In this review, we outline recent findings on miRNA functions and circulating miRNAs, and summarize the status of miRNAs as drug discovery candidates for breast cancer. In addition, we discuss the role of EVs in the clinical application of miRNAs.

METHODS
Relevant articles published from 2002 to 2021 were acquired (dated 31/03/2021) from PubMed database using the following key words: “miRNA” and “breast neoplasia”. Clinical trial data were retrieved from the database, ClinicalTrials.gov. This research was supported by AMED under Grant Number JP21ck0106555, and The Research Funding for Longevity Sciences (21-22) from the National Center for Geriatrics and Gerontology, Japan.

RESULTS
Functional roles of miRNAs in breast cancer
Increasing evidence has associated miRNA dysregulation with tumor progression and drug resistance in breast cancers (Figure 1). miRNAs in cancer are categorized as either oncogenic or tumor-suppressive depending on their action (Table 1). Certain miRNAs can exhibit dual functions, depending on the type of tissue. For example, miR-122, miR-22 and miR-93 have been reported to have dual functions in patients with breast cancer.

![Figure 1. Increase in the number of papers about miRNAs in cancer. Each line represents the numbers of papers as follows: dotted for cancer and solid for breast cancer, respectively.](image-url)
miRNAs are involved in metastatic processes. Cancer cells metastasize via their interactions with the tumor microenvironment. The tumor microenvironment is mostly composed of cancer-associated fibroblasts (CAFs), which are activated forms of fibroblasts. CAFs can remodel the composition and structure of the extracellular matrix to support tumor growth. Chatterjee et al. reported that miR-222 is involved in the reprogramming of CAFs. Wang et al. reported that EV-associated miR-181d-5p is

**Table 1.** List of functional miRNAs in breast cancer.

<table>
<thead>
<tr>
<th>Oncogenic miRNAs</th>
<th>Target process/signaling pathway</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-10b</td>
<td>Pro-metastatic genes</td>
<td>26</td>
</tr>
<tr>
<td>miR-105</td>
<td>Metabolic reprogramming of stromal cells</td>
<td>27</td>
</tr>
<tr>
<td>miR-122</td>
<td>Reprograming of glucose metabolism</td>
<td>28</td>
</tr>
<tr>
<td>miR-106b</td>
<td>PI3K/Akt pathway</td>
<td>25</td>
</tr>
<tr>
<td>miR-182-5p</td>
<td>TGF-β/SMAD pathway</td>
<td>29</td>
</tr>
<tr>
<td>miR-196a</td>
<td>Estrogen/SPRED1 cascade</td>
<td>30</td>
</tr>
<tr>
<td>miR-199a</td>
<td>Network that represses the expression of FOXP2</td>
<td>31</td>
</tr>
<tr>
<td>miR-21</td>
<td>Tumor cell apoptosis, IGF signaling</td>
<td>14, 32</td>
</tr>
<tr>
<td>miR-25-3p</td>
<td>Akt and MAPK/Erk pathways</td>
<td>33</td>
</tr>
<tr>
<td>miR-26a</td>
<td>Cell metabolism through targeting PDHX</td>
<td>34</td>
</tr>
<tr>
<td>miR-27b</td>
<td>EMT (H4K20/SUV420H2 axis)</td>
<td>36</td>
</tr>
<tr>
<td>miR-29a</td>
<td>Signaling pathways including Prlr/Stat5, TGF-β and Wnt/β-catenin</td>
<td>37</td>
</tr>
<tr>
<td>miR-31</td>
<td>PI3K/Akt pathway</td>
<td>25</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. The role of tumor-suppressive miRNAs.</th>
<th>Target process/signaling pathway</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-124</td>
<td>Survival and differentiation of osteoclast progenitor cells</td>
<td>38</td>
</tr>
<tr>
<td>miR-125b</td>
<td>Bone microenvironment promoting cancer spread</td>
<td>39</td>
</tr>
<tr>
<td>miR-190</td>
<td>TGF-β-induced EMT</td>
<td>40</td>
</tr>
<tr>
<td>miR-200 family</td>
<td>CAF activation and ECM remodeling</td>
<td>41, 42</td>
</tr>
<tr>
<td>miR-205</td>
<td>EMT</td>
<td>43</td>
</tr>
<tr>
<td>miR-206</td>
<td>EMT</td>
<td>44</td>
</tr>
<tr>
<td>miR-27b-3p</td>
<td>PI3K/Akt and MAPK/Erk pathways</td>
<td>45</td>
</tr>
<tr>
<td>miR-30a</td>
<td>EMT (p53/ZEB2 axis)</td>
<td>46</td>
</tr>
<tr>
<td>miR-3178</td>
<td>EMT (Notch1)</td>
<td>47</td>
</tr>
<tr>
<td>miR-34a</td>
<td>EMT, and M2 macrophage polarization (MCT-1/IL-6/IL-6R signaling)</td>
<td>48, 49</td>
</tr>
<tr>
<td>miR-375</td>
<td>EMT</td>
<td>50</td>
</tr>
<tr>
<td>miR-451</td>
<td>β-catenin/cyclin D1/c-Myc signaling</td>
<td>51</td>
</tr>
<tr>
<td>miR-770</td>
<td>Apoptosis</td>
<td>23, 52, 53</td>
</tr>
<tr>
<td>miR-17-92 cluster (miR-18a, miR-20a, miR-93)</td>
<td>EMT (SREBP1)</td>
<td>MAPK/Erk pathway and Akt phosphorylation</td>
</tr>
</tbody>
</table>

EMT: epithelial to mesenchymal transition, CAF: cancer-associated fibroblasts, ECM: extracellular matrix
miRNAs in breast cancer

secreted from CAFs and promotes tumor growth via the involvement of caudal-related homeobox 2 (CDX2) and homeobox A5 (HOXA5) proteins. miRNAs are also involved in breast cancer treatment. Some miRNAs are related to radio-sensitivity, while others are associated with drug resistance. Shen et al. reported that miR-195-5p, miR-203a-3p, and miR-9-5p are packed in EVs released by cells exposed to cytotoxic agents. The same study demonstrated that due to these miRNAs, the surrounding cancer cells acquired stem cell characteristics, resulting in drug resistance.

Breast cancer is treated with either anti-hormone therapy if the tumor is estrogen receptor (ER)/progesterone carbohy or with anti-human epidermal receptor 2 (HER2) therapy if the tumor is HER2-positive. ER/PgR-negative and HER2-negative breast cancer is defined as triple-negative breast cancer (TNBC); TNBC lacks potential drug targets. Recently, cyclin dependent kinase (CDK)4/CDK6 inhibitors have become the standard cytotoxic agents prescribed in ER/PgR-positive metastatic breast cancers (MBC). For example, miR-135a, miR-222, and miR-575 are involved in conferring resistance to tamoxifen, a drug frequently used in anti-hormone therapy; miR-126, miR-182, and miR-567 are involved in resistance to trastuzumab, which is the standard of anti-HER2 therapy. miRNA involvement has also been reported in drug resistance to palbociclib, a CDK4/6 inhibitor. Cornell et al. showed that EV-mediated miR-432-5p suppresses the TGF-β pathway and promotes the upregulation of CDK6, which consequently leads to palbociclib resistance; this oncogenic mechanism is different from that involving genetic abnormalities.

Circulating miRNAs as biomarkers of breast cancer

In breast cancer, carbohydrate antigen 15-3 (CA15-3) is the commonly used blood-based biomarker in clinical practice; however, it is considered a poor marker of breast cancer owing to its low sensitivity and specificity. Therefore, biomarkers that can sensitively reflect new diseases have been actively investigated. Numerous studies have suggested that miRNAs can be used in routine clinical practice as biomarkers for early breast cancer diagnosis, prediction of prognosis, and drug response. However, only a few results from these studies are reproducible due to population diversity and variation in research methods. Thus, we selected studies with sample sizes of more than 100 breast cancer patients with validated results since the miRNAs identified in these studies can be reproducible and potentially be used as biomarkers in clinical practice (Table 2).

Several clinical trials for the evaluation of circulating miRNAs have been conducted. A total of 10,631 clinical trials recorded before the end of March 2021 were returned after searching the database, ClinicalTrials.gov, using the term “breast cancer.” There are 50 studies focusing on the evaluation of miRNAs as biomarkers. From the database, 11 of these 50 clinical trials completed the observation period, but none of the results have been published.

There was a study using samples collected prospectively within the large context of international randomized clinical studies. Cosimo et al. examined the miRNA signatures associated with pathological complete response (pCR) using plasma samples from a NEoALTTO trial in which neoadjuvant anti-HER2 therapy (lapatinib and/or trastuzumab) was administered. Since achieving a pCR after systemic treatment correlates well with good prognosis, pCR is often used for the assessment of therapeutic effects instead of examining overall survival (OS). The authors identified miRNA signatures that discriminate patients with pCR after neoadjuvant therapy and demonstrated that miR-140-5p levels 2 weeks after the start of trastuzumab correlated with event-free survival.

A study using large-scale clinical samples was conducted by Shimomura et al. through a microarray profiling using miRNAs obtained from 1,280 breast cancer patients, 2,836 controls, 451 patients with other cancer types, and 63 women with benign breast disease. The authors identified a panel of five miRNAs that distinguished between breast cancer, other cancers, and controls.

With respect to prognostic biomarkers for operable breast cancer, Wang et al. identified a panel of five miRNAs (miR-130b-5p, miR-151a-5p, miR-206, miR-222-3p, and miR-943). The authors reported that patients with three or more highly-expressed miRNAs among the identified panel had shorter disease-free survival than those with 0 to 2 highly-expressed miRNAs after breast cancer radical surgery. In MBC, circulating tumor cells (CTCs) are prognostic biomarkers approved by the US Food and Drug Administration (FDA). However, their use is limited by the enrichment and detection methods used, making them difficult biomarkers to access in routine clinical practice. Therefore, there is still a need for a novel biomarker that can be easily measured. Madhavan et al. studied a miRNA signature that can be effectively used in a metastatic setting. First, they examined the miRNAs associated with CTCs in MBC and identified a panel of 16 miRNAs that could predict the OS rate in MBC.
They also showed that the patients with recurrence within 2 years could be identified earlier than in clinical diagnosis using a signature composed of six miRNAs from the identified panel (miR-200a, miR-200b, miR-200c, miR-210, miR-215, and miR486-5p). They also showed that the patients with recurrence within 2 years could be identified earlier than in clinical diagnosis using a signature composed of six miRNAs from the identified panel (miR-200a, miR-200b, miR-200c, miR-210, miR-215, and miR486-5p).<ref>

**Table 2. Circulating miRNAs as promising biomarkers.**

<table>
<thead>
<tr>
<th>Sample Source</th>
<th>Sample Number</th>
<th>miRNAs</th>
<th>Assessment</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma</td>
<td>627</td>
<td>miR-127-3p, miR-148b, miR-376a, miR-376c, miR-409-3p, miR-652, and miR-801</td>
<td>Higher in BC</td>
<td>63</td>
</tr>
<tr>
<td>Serum</td>
<td>164</td>
<td>miR-1, miR-92a, miR-133a, and miR-133b</td>
<td>Higher in BC</td>
<td>64</td>
</tr>
<tr>
<td>Plasma</td>
<td>172</td>
<td>miR-148b, and miR-133a</td>
<td>Higher in BC</td>
<td>65</td>
</tr>
<tr>
<td>Serum</td>
<td>108</td>
<td>miR-15a, miR-18a, miR-107, and miR-425</td>
<td>Higher in BC</td>
<td>66</td>
</tr>
<tr>
<td>Serum</td>
<td>137</td>
<td>miR-484</td>
<td>Higher in BC</td>
<td>67</td>
</tr>
<tr>
<td>Plasma</td>
<td>199</td>
<td>miR-505-5p, miR-125-5p, miR-21-5p, and miR-96-5p</td>
<td>Higher in BC</td>
<td>68</td>
</tr>
<tr>
<td>Serum</td>
<td>1280</td>
<td>miR-1246, miR-1307-3p, and miR-6861-5p</td>
<td>Higher in BC</td>
<td>69</td>
</tr>
<tr>
<td>Plasma</td>
<td>215</td>
<td>miR-16, miR-148a, and miR-19b</td>
<td>Higher in BC</td>
<td>70</td>
</tr>
<tr>
<td>Serum</td>
<td>158</td>
<td>let-7d, let-7i, miR-103, miR-107, and miR-22*</td>
<td>Lower in BC</td>
<td>71</td>
</tr>
<tr>
<td>Plasma</td>
<td>257</td>
<td>miR-155, miR-574-5p, and MALAT</td>
<td>Higher in BC</td>
<td>72</td>
</tr>
<tr>
<td>Plasma/Serum</td>
<td>200/204</td>
<td>let-7a</td>
<td>Lower in BC</td>
<td>73</td>
</tr>
<tr>
<td>Plasma</td>
<td>193</td>
<td>miR106a-3p, miR106a-5p, miR20b-5p, and miR92a-2-5p (Plasma)</td>
<td>Higher in BC (Plasma)</td>
<td>74</td>
</tr>
<tr>
<td>Plasma</td>
<td>193</td>
<td>miR106a-5p, miR19b-3p, miR20b-5p, and miR92a-3p (Serum)</td>
<td>Higher in BC (Serum)</td>
<td>75</td>
</tr>
<tr>
<td>Plasma</td>
<td>1254</td>
<td>miR-24-3p</td>
<td>Predicting OS for BC</td>
<td>76</td>
</tr>
<tr>
<td>Serum</td>
<td>130</td>
<td>miR-18b, miR-103, miR-107, and miR-652</td>
<td>Predicting relapse in TNBC</td>
<td>77</td>
</tr>
<tr>
<td>Plasma</td>
<td>612</td>
<td>miR141, miR-200a, miR-200b, miR-200c, miR-203, miR-210, miR-375, and miR801</td>
<td>Higher in CTC-positive MBC</td>
<td>78</td>
</tr>
<tr>
<td>Plasma</td>
<td>429</td>
<td>miR-140-5p</td>
<td>Predicting Response to neoadjuvant trastuzumab for HER2-positive BC</td>
<td>79</td>
</tr>
<tr>
<td>Serum</td>
<td>565</td>
<td>miR-940, miR-451a, miR-16-5p, and miR-17-3p</td>
<td>Predicting Response to trastuzumab for HER2-positive MBC</td>
<td>80</td>
</tr>
</tbody>
</table>


It has been demonstrated that miRNAs may be used as anti-cancer drug agents depending on their expression levels in the tumor tissues. Vectors, miRNA mimics, and small molecule compounds are used to supplement tumor-suppressive miRNAs, while antisense miRNAs (anti-miRs), miRNA sponges, and decoy vectors are used to suppress oncogenic miRNAs. Agents most frequently used in in vitro and in vivo experiments are miRNA mimics.
and locked nucleic acids (LNA)-modified anti-miRs. miRNA mimics are double-stranded synthetic RNAs that mimic endogenous miRNAs, while LNA-modified anti-miRs are anti-miRs that are chemically locked by a bridge that connects the 2′-oxygen and 4′-carbon in a ribonucleotide. Due to this bridge, LNA-modified anti-miRs achieve stable regulation with simple manipulations.

In clinical practice, drugs targeting miRNAs are expected to be used as a combination therapy with other drugs to enhance their therapeutic effects and weaken the resistance to these drugs. In breast cancer, miR-10b plays an important role in metastasis.\textsuperscript{26} Antisense miR-10b is ineffective in shrinking primary tumors but is effective for metastatic lesions.\textsuperscript{80} Yoo et al. showed that the combination of antisense miR-10b with cytotoxic agents after excision of the primary lesion eliminated metastatic lesions without systemic toxicity.\textsuperscript{81} The authors used dextran-coated iron oxide nanoparticles (MN-anti-miR-10b) to effectively reach target tissues. Interestingly, MN-anti-miR-10b suppressed brain metastasis, even when used as a monotherapy.\textsuperscript{82} Gao et al. demonstrated that miR-873 is involved in PDL1-mediated acquisition of stem cell traits, suggesting that drugs targeting the miR-873 axis can be used in combination with immune checkpoint blockers.\textsuperscript{83} In TNBC, effective drugs are scarce, and its prognosis is poor. One of the emerging investigational strategies for treating TNBC is to induce \textit{HER2} expression, thus sensitizing it to anti-\textit{HER2} therapy. Ninio-Many \textit{et al.} demonstrated that miR-125a-3p induced \textit{HER2} expression, allowing TNBC cell lines to respond to anti-\textit{HER2} therapy.\textsuperscript{84}

Various clinical trials for anti-cancer drugs targeting miRNAs have been conducted (Table 3). The most studied drug that targets miRNAs is the miR-34 mimic represented by MRX34. A multicenter phase I trial in 2013 was conducted to study the effects of MRX34 in patients with advanced solid tumors, primarily liver cancer.\textsuperscript{85} Subsequently, patients with liver metastases including those with breast cancer also participated in the trial. However, this trial was terminated due to immune-related adverse events that led to the death of a patient. On the other hand, cobomarsen, an anti-miR-155 agent, has already been approved by the FDA as an orphan drug for mycosis fungoides cutaneous T-cell lymphoma.

**Table 3. Clinical trials using miRNAs as anti-cancer drugs.**

<table>
<thead>
<tr>
<th>Therapeutic agent</th>
<th>Carrier</th>
<th>Disease</th>
<th>Clinical trial phase</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-34 mimic</td>
<td>Liposomal carrier</td>
<td>Liver and solid cancer</td>
<td>Phase I (NCT01829971)</td>
<td>Terminated</td>
</tr>
<tr>
<td>(MRX34)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-16 mimic</td>
<td>EnGeneIC Delivery Vehicle</td>
<td>NSCLC and Malignant pleural mesothelioma</td>
<td>Phase I (NCT02369198)</td>
<td>Completed</td>
</tr>
<tr>
<td>(TargomiR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-miR-155</td>
<td>Oligonucleotide inhibitor</td>
<td>Lymphoma and leukemia</td>
<td>Phase I (NCT02580552)</td>
<td>Completed</td>
</tr>
<tr>
<td>(Cobomarsen)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-miR-155</td>
<td>Oligonucleotide inhibitor</td>
<td>CTL (Mycosis fungoides type)</td>
<td>Phase II (NCT03713320)</td>
<td>Terminated</td>
</tr>
<tr>
<td>(Cobomarsen)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-miR-10b</td>
<td>Oligonucleotide inhibitor</td>
<td>Glioblastoma</td>
<td>Phase I (NCT01849952)</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>

NSCLC: non-small cell lung cancer, CTL: cutaneous T-cell lymphoma

**DISCUSSION**

Blood, saliva, and urine can be used to assess the levels of miRNAs. Testing for miRNAs has become easy to incorporate into routine medical care, leading to a high accuracy of diagnosis and efficient monitoring of the treatment. However, several issues need to be resolved before they can be used clinically.\textsuperscript{86} In the pre-analysis stage, various patient factors must be considered such as the patient’s diet, medication intake, and age, as well as laboratory factors such as sample collection method and handling. Although reliable methods for measuring the levels of miRNAs (polymerase chain reaction (PCR)-based, microarray, and next-generation sequencing) are available, significant inter-platform differences have been pointed out. Currently, quantitative PCR is considered the gold standard technique. In the post-analysis stage, the primary concern is the absence of a standardized data normalization method.

There are currently no approved liquid biopsies for breast cancer. However, cell-free DNAs (cf-DNAs) are the clinically-used biomarkers for the detection of epidermal growth factor receptor (EGFR) mutations in lung cancers. The detection rates of EGFR mutations were improved by using a combination of cf-DNAs and EVs.\textsuperscript{87} Although the identified EVs may differ between studies, early diagnosis may be achieved by using miRNAs detected in EVs from breast cancer patients.\textsuperscript{88,89} It should be noted that there is no consensus on the markers that label EVs in human samples.\textsuperscript{12,13} However, these studies suggested that
miRNAs in cancer EVs can be used as potential biomarkers that reflect the state of the disease.

While drugs targeting one molecule are considered mainstream, drugs targeting miRNAs can regulate several genes with one agent producing unprecedented therapeutic effects. Furthermore, they are easier to screen for highly effective read sequences than chemically synthesized drugs, and the obtained read sequences can be used as new drugs. Therefore, once the development scheme is completed, rapid development can be achieved. The development of a drug delivery system (DDS) is essential for drugs targeting miRNAs.  DDS using viral vectors is not ideal for clinical settings owing to the risk of strong inflammation. Attempts have been made to attach aptamers and ligands to drugs that target miRNAs. It has become possible to deliver drugs stably and safely to target tissues by encapsulation in EVs. For the routine application of drugs targeting miRNAs in cancer, it is necessary to monitor the long-term effects at the pre-clinical stages and to consider immune-related side effects.

**CONCLUSION**

In summary, miRNAs in breast cancer are in the early stages of clinical application as biomarkers and therapeutic targets, and their application is likely to dramatically change the clinical practice. In addition, EVs will be key to expanding the range of applications of miRNAs. With regard to the versatility of clinical applications, reviewing what we already know regarding miRNAs in breast cancer is vital before conducting further research.

**ACKNOWLEDGEMENTS**

We would like to thank Editage (www.editage.com) for editing the manuscript.

**CONFLICT OF INTEREST**

There are no conflicts of interest to declare through all steps of this study.

**REFERENCES**


33. Chen H, Pan H, Qian Y, Zhou W, Liu X. MiR-25-3p promotes the proliferation of triple negative breast...


miRNAs in breast cancer


miRNAs in breast cancer


miRNAs in breast cancer


How to Cite This Article